Quantumzyme Expands AI Enzyme Platform to Target Additional High-Volume Pharmaceuticals

Quantumzyme Corp. has announced the expansion of its proprietary AI-powered enzyme design platform to target additional high-volume Active Pharmaceutical Ingredients beyond ibuprofen, marking a significant advancement in green pharmaceutical manufacturing. This strategic initiative aims to reduce hazardous waste, toxic solvent use, and carbon emissions at scale while addressing the environmental impact of global API production. The expanded program leverages Quantumzyme's enzyme families, machine learning predictive models, and in silico design workflows to develop sustainable pathways for other APIs with significant global environmental impact.

The company's enzyme engineering platform integrates advanced AI-driven computational modeling, in silico directed evolution, mechanistic simulation, and high-throughput validation to deliver optimized biocatalysts that replace traditional energy-intensive chemical reaction steps. The expanded R&D pipeline includes multiple high-volume APIs, including chiral intermediates such as phenylephrine and related compounds accessible via ketoreductases, which are widely used in the global generics sector. This expansion demonstrates the scalability of Quantumzyme's digital biology architecture and its ability to rapidly adapt and redeploy enzyme systems across diverse synthesis targets.

Naveen Kulkarni, CEO of Quantumzyme, noted that the global API market is projected to exceed $300 billion USD by 2030, with generic drugs representing the majority of production volume. Much of this manufacturing currently occurs overseas using legacy chemistries that generate heavy waste streams and carry high solvent and carbon intensity. The company's goal is to develop an approach that is both sustainable and eco-friendly. Quantumzyme's biocatalysis-first approach offers a sustainable alternative that delivers reduced chemical waste and solvent usage, lower carbon footprint, elimination of toxic reagents, and improved cost and yield efficiency.

The company's platform also supports domestic API manufacturing and aligns with U.S. supply chain resilience and sustainability goals. For more information, visit https://www.quantumzymecorp.com and the company's profile at https://www.otcmarkets.com/stock/QTZM. Kulkarni added that by extending the enzyme engineering platform beyond ibuprofen, the company is advancing greener chemistry, supporting supply chain resiliency, and moving closer to a future where enzyme-driven production becomes the industry standard for high-volume APIs. This expansion represents a significant step toward redefining chemical manufacturing through sustainable innovation in the pharmaceutical sector.